Micot
Micot is a peptide and protein drug developer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | $27.9m Valuation: $232m | Series D | |
| Total Funding | 000k | ||
Related Content
Shaanxi Micot Technology Co., Ltd. is a clinical-stage biopharmaceutical firm established in January 2007 by founder Dr. Wang Bing. Headquartered in Xi'an, China, the company has expanded its operations to include locations in Suzhou, Beijing, Shanghai, and the United States. Micot specializes in the discovery and development of peptide-based therapeutics, particularly focusing on bifunctional and multifunctional peptides to address unmet clinical needs.
The company's core business revolves around creating new drugs for significant health challenges. Its development pipeline targets a range of therapeutic areas, including cardiovascular and metabolic diseases, renal and bone-related complications, inflammatory disorders, and pain management. Micot operates on a model of internal research and development, leveraging four integrated technology platforms: a bispecific polypeptide technology platform, a computer-aided peptide design platform, a developability assessment platform, and a macromolecular platform. This structure enables the firm to develop a robust pipeline of what it terms "First-in-class" and "Best-in-class" drug candidates.
Micot's product portfolio contains over 20 polypeptide drug candidates, with several advancing to late-stage clinical trials in both China and the U.S. One notable candidate is MT-1011, a small-molecule anticoagulant antagonist designed to reverse the effects of anticoagulants and control bleeding. Another key product in development, MT-1009, is a bifunctional peptide for treating osteoporosis. The company has successfully raised significant capital to fund its clinical trials and pipeline expansion, including a Series B round of ¥360 million in May 2021, a Series C of over ¥100 million in February 2023, and a Series D round of $14 million in July 2025.
Keywords: biopharmaceutical, peptide therapeutics, drug discovery, clinical-stage, cardiovascular diseases, metabolic diseases, polypeptide drugs, new drug development, pharmaceutical R&D, bifunctional peptides, anticoagulant, osteoporosis treatment, inflammatory disorders, renal disease, China biotech, Xi'an, Wang Bing, injectable drugs, peptide design, clinical trials